Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Leukemia, Myeloid, Acute 77Leukemia 74Leukemia, Lymphocytic, Chronic, B-Cell 68Myelodysplastic Syndromes 56Lymphoma 49Precursor Cell Lymphoblastic Leukemia-Lymphoma 47Lymphoma, Non-Hodgkin 45Multiple Myeloma 43Leukemia, Myelogenous, Chronic, BCR-ABL Positive 38Hodgkin Disease 36Melanoma 25Hematologic Neoplasms 25Recurrence 19Neoplasms 17Myeloproliferative Disorders 17Neoplasm Metastasis 15Lymphoma, Follicular 15Primary Myelofibrosis 14Neoplasms, Plasma Cell 14Lymphoma, Large B-Cell, Diffuse 14Lymphoma, Mantle-Cell 13Skin Neoplasms 11Graft vs Host Disease 11Burkitt Lymphoma 11Anemia, Refractory, with Excess of Blasts 11Lymphoma, B-Cell, Marginal Zone 10Lymphoma, B-Cell 10Leukemia, Myelomonocytic, Chronic 9Hematologic Diseases 8Breast Neoplasms 8

Interventions

Cyclophosphamide 4Prednisone 3Doxorubicin 3prednylidene 2deltacortene 2Vorinostat 2Vincristine 2Etoposide 2Brentuximab Vedotin 2pembrolizumab 1fludarabine phosphate 1fludarabine 1etoposide phosphate 1Receptors, Chimeric Antigen 1Peripheral Blood Stem Cell Transplantation 1Nivolumab 1MLN 8237 1Lenalidomide 1Ki-1 Antigen 1Bortezomib 1Automobiles 110-propargyl-10-deazaaminopterin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Enteropathy-Associated T-Cell Lymphoma × fludarabine × Clear all
NCT03049449 2023-01-18

T Cells Expressing a Fully-Human Anti-CD30 Chimeric Antigen Receptor for Treating CD30-Expressing Lymphomas

National Institutes of Health Clinical Center (CC)

Phase 1 Completed
26 enrolled 19 charts
Lymphoid

Immunoblastic Lymphadenopathy, Lymphoma, Large B-Cell, Diffuse, Lymphoma, T-Cell, Peripheral, Lymphoma, Large-Cell, Anaplastic, Lymphoma, Extranodal NK-T-Cell, Enteropathy-Associated T-Cell Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡